EWTX
Edgewise Therapeutics, Inc.
$39.56
+0.41 (+1.05%)
At close · Jul 2
Market Cap
$4.26B
Shares
107,593,006
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.56
Open$39.15
Day$38.36–39.81
52W$12.30–43.93
Avg vol 30d1.5M
Short int9.9M · 9.2% float · 5.7d
Short vol74%
Last earningsMay 7, 2026
DataMar 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+46% above
+
Price vs 50-day avg
+13% above
◦
RSI (14)
58 · neutral
+
MACD trend
positive
+
52-week position
86% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $35 › 200d $27 — 50d above 200d
−
Institutional flow
4 of 216 funds reported for Jun 30 · net -198 sh shares
−
Insider flow
Net -$2.1M over 90 days · 100% sells
+
Short interest
9.23% of float · ▼ -9.0% MoM · 5.7 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
216 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−12% Y/Y
−
Free cash flow
$-144.1M
+
Balance sheet
net cash $61.1M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+46% above
Bullish
Price vs 50-day avg
+13% above
Bullish
RSI (14)
58 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
86% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $35 › 200d $27 — 50d above 200d
Institutional flow
Distributing
4 of 216 funds reported for Jun 30 · net -198 sh shares
Insider flow
Distributing
Net -$2.1M over 90 days · 100% sells
Short interest
Falling
9.23% of float · ▼ -9.0% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
216 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $12
Now $40 · 86%
52-wk high $44
vs 200-day avg +46%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EWTX
this stock
Edgewise Therapeutics, Inc.
|
$4.26B | +59.4% | — | — | 9.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EWTX | -5.1% | +9.3% | +58.4% | -2.6% | +59.4% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -6.5% | +10.5% | +50.4% | -2.4% | +50.2% |